Key result
Continuing chronic beta-blockers upon admission for suspected infection is linked to ~23% lower 90-day mortality.
Why the study?
Despite potential benefits in septic shock, chronic beta-blockers are often held at hospital admission for patients with suspected infection and possible sepsis.
Does continuation of oral beta-blockers reduce 90-day all-cause mortality in patients on chronic beta-blockers admitted with suspected infection?
Cohort (n=4,635)
No
Does continuation of oral beta-blockers reduce 90-day all-cause mortality in patients on chronic beta-blockers admitted with suspected infection?
Hazard Ratio: 0.77 (95% CI 0.61–0.98)
p-value: p=0.03
Continuing chronic oral beta-blockers in patients admitted with suspected infection is associated with lower 90-day mortality and shorter hospital stays compared to withholding them.
Hypothesis-generating for continuing beta-blockers in suspected infection; randomized trials needed before practice change.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Christian‐Miller et al. (2026) conducted a cohort in suspected infection (n=4,635). Continuation of oral beta-blockers vs. Discontinuation of oral beta-blockers was evaluated on 90-day all-cause mortality (HR 0.77, 95% CI 0.61-0.98, p=0.03). Continuation of chronic beta-blockers upon admission for suspected infection was associated with a reduced risk of 90-day all-cause mortality (HR 0.77; 95% CI 0.61-0.98; p=0.03).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: